The key to combating cancer lies in understanding the ways it operates. Like for all cancers, early diagnosis presents the best chances of survival. Unfortunately, lung cancer often remains undiagnosed until it's too late.

For this reason, a critical component of our strategy against lung cancer is exploring how diagnostic tools – tissue biopsy, liquid biopsy, immunoassay and imaging technologies – can complement one another and ensure patients are presented with the best solutions at every stage.

Moreover, at the root of our significant advancements is a focus on understanding the genetics and disease pathways behind cancer. Genomic testing and advanced diagnostics can identify mutations in patients to predict the best therapy for the best possible outcomes, ultimately giving physicians and other healthcare professionals the ability to deliver truly personalised healthcare . Although no single intervention is likely to cure cancer—and there is much work left to do—new possibilities are changing perspectives and prognoses.